Delfi Diagnostics

Active#2 worldwide · In-vitro diagnostics

Estimated valuation · In-vitro diagnostics · United States

Develops low-cost blood tests that analyse cell-free DNA fragmentation patterns with machine learning to detect lung and other cancers early, sold through physicians.

Healthtech›In-vitro diagnostics delfidiagnostics.com

HQUnited States

Last roundSeries B · Jul 2022

Estimated valuation

AI · In-vitro diagnostics ranking (worldwide)

≈ USD 1.2bnUSD 770M–1.7bn · Unicorn

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Series B · USD 225M · Jul 2022

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
In-vitro diagnostics · worldwide	Top 25	#2	Edition 0 · Oct 2026	12 Apr 2027

Rank historyOct 2026 · #2 In-vitro diagnosticsFirst edition: no movements yet.

Funding history

Date	Round	Amount	Type	Investors
Jul 2022	Series B	USD 225M	Equity	DFJ Growth, Eli Lilly, Point72, Brown Advisory, Cowen Healthcare Investments

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Delfi Diagnostics as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $1.2BUndervalued or overvalued?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Delfi Diagnostics whether or not it has agreed: your intention joins the pool on Delfi Diagnostics, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Delfi Diagnostics Or back healthtech in United States

Pool on Delfi DiagnosticsBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Delfi Diagnostics?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in in-vitro diagnostics

Full in-vitro diagnostics ranking →

Function Health#1United StatesUnicorn Everlywell#3United StatesHundreds of M$LetsGetChecked#4IrelandHundreds of M$Harbinger Health#5United StatesHundreds of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.